Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 14/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 14/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4427015 | 1.00 | ITGB3 (0.47) | ITGB3ITGA2BMAOBSCN3AS1PR1 | |
| SCHEMBL4563539 | 0.90 | SCN3A (0.52) | ITGB3ITGA2BMAOBSCN3A | |
| SCHEMBL4427021 | 0.90 | SCN3A (0.52) | ITGB3ITGA2BMAOBSCN3A | |
| SCHEMBL3505885 | 0.87 | ITGB3 (0.58) | ITGB3ITGA2BMAOB | |
| SCHEMBL3506689 | 0.87 | ITGB3 (0.58) | ITGB3ITGA2BMAOB | |
| SCHEMBL3505888 | 0.87 | ITGB3 (0.58) | ITGB3ITGA2BMAOB | |
| SCHEMBL4419049 | 0.86 | ITGB3 (0.47) | ITGB3ITGA2BSCN3A | |
| SCHEMBL4419052 | 0.86 | ITGB3 (0.47) | ITGB3ITGA2BSCN3A | |
| SCHEMBL4420034 | 0.85 | ITGB3 (0.54) | ITGB3ITGA2B | |
| SCHEMBL4420029 | 0.85 | ITGB3 (0.54) | ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501804-B1 | ISOQUINOLINE DERIVATIVES MAO-B INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-08-26 | — | — | EP | disclosed |
| US-6818774-B2 | 2-(S)-(6-(4-FLUORO-BENZYLOXY)-3-OXO-3,4-DIHYDRO-1H-ISOQUINOLIN -2-YL)- PROPIONAMIDE FOR EXAMPLE; ALZHEIMER'S DISEASE OR SENILE DEMENTIA | HOFFMAN-LA ROCHE INC. | 2004-11-16 | — | — | US | disclosed |
| US-20030225122-A1 | 2-(S)-(6-(4-fluoro-benzyloxy)-3-oxo-3,4-dihydro-1H-isoquinolin -2-yl)- propionamide for example; Alzheimer's disease or senile dementia | HOFFMANN-LA ROCHE INC. | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030225122-A1 | 2-(S)-(6-(4-fluoro-benzyloxy)-3-oxo-3,4-dihydro-1H-isoquinolin -2-yl)- propionamide for example; Alzheimer's disease or senile dementia | MAOB, MAOA, BACE2 | ITGB3 3585/4885ITGA2B 2312/4885MAOB 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.